Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

        Training and Continuing Education

Guidance Webinar Series Home
          Training and Continuing Education
          Guidance Webinar SeriesTraining and Continuing Education Guidance Webinar Series
  	
        Share
    Post
    Linkedin

    Email
    PrintFDA's Guidance Webinar series aims to foster collaboration and transparency in the development of guidance documents through direct outreach to affected stakeholders.

The first-in-a-series of Guidance Webinars presented an overview of the draft guidance Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring and provided a real-time question and answer session with the guidance's primary authors.

Additional Recorded Webinars

Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
	Pathologic Complete Response in Neoadjuvant Treatment of High Risk Early-Stage Breast Cancer:  Use as an Endpoint to Support Accelerated ApprovalArchived webinars, transcripts, and audience questions are available in the list below:

FDA Guidance Webinars Online-Access Instructions: Access Guidance Webinars

Each webinar will be recorded and streaming links to access the recordings will be available after each session, along with relevant meeting materials on this website.

**2011 - 2015 webinars are archived. To view them, please see the**FDA Archive
To **view the webinars**, copy and paste the web address starting with **https:// into a web browser**.



Past Webinars

FDA Webinar: Draft Guidance: Use of an Electronic Informed Consent in Clinical Investigations Questions and Answers - April 20, 2015
	FDA Webinar: Draft Guidance for Industry (GFI) Uncomplicated Gonorrhea: Developing Drugs for Treatment - September 11, 2014
	FDA Webinar: Guidance for Industry Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis: Developing Drug Products for Treatment - April 23, 2014
	FDA Webinar: Final GFI: Electronic Source Data In Clinical Investigations (Procedural) - January 29, 2014
	CDER Small Business Webinar on Stability Guidance for ANDAs, and draft Questions and Answers guidance considerations - November 4, 2013
	FDA Webinar: 60-Day Draft GFI On Antibacterial Therapies For Patients With Unmet Medical Need For The Treatment Of Serious Bacterial Diseases - September 27, 2013
	FDA Webinar: Draft GFI On Expedited Programs For Serious Conditions Drugs And Biologics - August 5, 2013
	FDA Webinar: Webinar Draft GFI on Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment; Availability - July 25, 2013
	FDA Webinar: Webinar Draft GFI On Rheumatoid Arthritis - Developing Drug Products For Treatment; Availability - July 25, 2013
	FDA Webinar: Draft Guidance For Industry On Alzheimers Disease: Developing Drugs For The Treatment Of Early Stage Disease; Availability - March 28, 2013
	FDA Webinar: Webinar Draft GFI On Enrichment Strategies For Clinical Trials To Support Approval Of Human Drugs And Biological Products - March 25, 2013
	FDA Webinar: New Draft Guidance on "FDA Guidance for Industry Webinar on Draft Guidance Vaginal Microbicides: Development for the Prevention of HIV Infection" - January 22, 2013
	FDA Webinar: 60-Day Draft Guidance on Using an Endpoint to Support Accelerated Approval of Drugs to Treat Early-Stage Breast Cancer - June 28, 2012
	FDA Webinar: New Draft Guidance on Safety Data Collection - March 27, 2012
	Guidance Webinar: Oversight of Clinical Investigations--A Risk-Based Approach to Monitoring - October 24, 2011

                                                                                  Content current as of:
      02/08/2023
                  
                   
Regulated Product(s)
		 DrugsGuidance Webinar Series
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop